Linda Stein Gold, MD

Dermatologists discuss the profound impact of seborrheic dermatitis on an individual’s quality of life, discussing self-reported effects on self-esteem, social interactions, and career trajectories.

Expert dermatologist Dr Linda Stein Gold discusses the pathophysiology of psoriasis as target for treatment.

Dr Linda Stein Gold discusses the effect that plaque psoriasis in special areas can have on the quality of life of a patient.

Dermatologists discuss differentiating seborrheic dermatitis from conditions like psoriasis, eczema, and lupus, highlighting similarities and differences with other skin conditions.

Dermatologists introduce this series providing and overview of seborrheic dermatitis (SD), highlighting common causes, contributing factors, and the various ways it may present in different patient populations.

Brad Glick, DO, MPH; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, comment on the future of plaque psoriasis treatment and share clinical pearls on the management of plaque psoriasis.

Expert dermatologists comment on the use of nonsteroidal topical therapies in the treatment of plaque psoriasis and how it has affected clinical practice.

Experts discuss the DERMIS clinical trials of roflumilast in the treatment of plaque psoriasis, highlighting its efficacy in the intertriginous areas.

Mona Shahriari, MD, and Linda Stein Gold, MD, review the long-term safety and efficacy data of tapinarof as well as its use in clinical practice for the management of plaque psoriasis.

Experts in dermatology discuss recent advances in the plaque psoriasis treatment toolbox, highlighting the mechanism of action and data of tapinarof.

Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.

Experts share the difference between the remittive and the suppressive effect in plaque psoriasis and how to get patients there.

Expert dermatologists discuss plaque psoriasis in difficult-to-treat areas such as skin folds and the face, highlighting which types of treatments they recommend.

Linda Stein Gold, MD; Mona Shahriari, MD; and Michael Cameron, MD, FAAD, share approaches to choosing between systemic and topical therapies or combination therapies to treat plaque psoriasis.

Experts discuss the current standard of care for patients with moderate-to-severe plaque psoriasis, focusing on whether the patient is a candidate for systemic or topical treatment.

Expert dermatologists provide an overview of the current topical, oral, and biologic medications available to treat plaque psoriasis.

Linda Stein Gold, MD, and Mona Shahriari, MD, comment on the psychological impact plaque psoriasis has on patients, garnering an increased risk of anxiety and depression.

Brad Glick, MD; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, provide an overview of plaque psoriasis, highlighting demographics and risk factors, as well as the pathophysiology of the disease.

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, review the clinical and practical impact of TYK2 inhibition and its evolving role within the treatment landscape for psoriatic disease.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the potential use of TYK2 inhibitors in combination with other modalities.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, share considerations for ensuring that patients on Medicare and Medicaid receive the appropriate medication.

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.